Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).

TOPN regulates PD-L1 expression through the NF-κB pathway in NSCLS, which is a potential independent biomarker and target for prognosis as well as immunotherapy.